DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Purpose

This clinical trial studies nivolumab and ipilimumab in treating patients with rare tumors. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread.

    •    Acinar Cell Carcinoma
    •    Adenoid Cystic Carcinoma
    •    Adrenal Cortex Carcinoma
    •    Adrenal Gland Pheochromocytoma
    •    Anal Canal Neuroendocrine Carcinoma
    •    Anal Canal Undifferentiated Carcinoma
    •    Appendix Mucinous Adenocarcinoma
    •    Bartholin Gland Transitional Cell Carcinoma
    •    Bladder Adenocarcinoma
    •    Cervical Adenocarcinoma
    •    Cholangiocarcinoma
    •    Chordoma
    •    Colorectal Squamous Cell Carcinoma
    •    Desmoid-Type Fibromatosis
    •    Endometrial Transitional Cell Carcinoma
    •    Endometrioid Adenocarcinoma
    •    Esophageal Neuroendocrine Carcinoma
    •    Esophageal Undifferentiated Carcinoma
    •    Extrahepatic Bile Duct Carcinoma
    •    Fallopian Tube Adenocarcinoma
    •    Fallopian Tube Transitional Cell Carcinoma
    •    Fibromyxoid Tumor
    •    Gastric Neuroendocrine Carcinoma
    •    Gastric Squamous Cell Carcinoma
    •    Gastric Undifferentiated Carcinoma
    •    Gastrointestinal Stromal Tumor
    •    Giant Cell Carcinoma
    •    Intestinal Neuroendocrine Carcinoma
    •    Intrahepatic Cholangiocarcinoma
    •    Lung Carcinoid Tumor
    •    Lung Sarcomatoid Carcinoma
    •    Major Salivary Gland Carcinoma
    •    Malignant Odontogenic Neoplasm
    •    Malignant Peripheral Nerve Sheath Tumor
    •    Malignant Testicular Sex Cord-Stromal Tumor
    •    Metaplastic Breast Carcinoma
    •    Metastatic Malignant Neoplasm of Unknown Primary Origin
    •    Minimally Invasive Lung Adenocarcinoma
    •    Mixed Mesodermal (Mullerian) Tumor
    •    Mucinous Adenocarcinoma
    •    Mucinous Cystadenocarcinoma
    •    Nasal Cavity Adenocarcinoma
    •    Nasal Cavity Carcinoma
    •    Nasopharyngeal Carcinoma
    •    Nasopharyngeal Papillary Adenocarcinoma
    •    Nasopharyngeal Undifferentiated Carcinoma
    •    Oral Cavity Carcinoma
    •    Oropharyngeal Undifferentiated Carcinoma
    •    Ovarian Adenocarcinoma
    •    Ovarian Germ Cell Tumor
    •    Ovarian Mucinous Adenocarcinoma
    •    Ovarian Squamous Cell Carcinoma
    •    Ovarian Transitional Cell Carcinoma
    •    Pancreatic Acinar Cell Carcinoma
    •    Pancreatic Neuroendocrine Carcinoma
    •    Paraganglioma
    •    Paranasal Sinus Adenocarcinoma
    •    Paranasal Sinus Carcinoma
    •    Parathyroid Gland Carcinoma
    •    Pituitary Gland Carcinoma
    •    Placental Choriocarcinoma
    •    Placental-Site Gestational Trophoblastic Tumor
    •    Primary Peritoneal High Grade Serous Adenocarcinoma
    •    Pseudomyxoma Peritonei
    •    Rare Disorder
    •    Scrotal Squamous Cell Carcinoma
    •    Seminal Vesicle Adenocarcinoma
    •    Seminoma
    •    Serous Cystadenocarcinoma
    •    Small Intestinal Adenocarcinoma
    •    Small Intestinal Squamous Cell Carcinoma
    •    Spindle Cell Neoplasm
    •    Squamous Cell Carcinoma of the Penis
    •    Teratoma With Malignant Transformation
    •    Testicular Non-Seminomatous Germ Cell Tumor
    •    Thyroid Gland Carcinoma
    •    Tracheal Carcinoma
    •    Transitional Cell Carcinoma
    •    Ureter Adenocarcinoma
    •    Ureter Squamous Cell Carcinoma
    •    Urethral Adenocarcinoma
    •    Urethral Squamous Cell Carcinoma
    •    Vaginal Adenocarcinoma
    •    Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
    •    Vulvar Carcinoma

Keywords

rare cancer, bladder cancer, carcinoma

Principal Investigator

Thomas J George, Jr, M.D.

Department

MD-HEMATOLOGY/ONCOLOGY

Contact Information

tgeorge@ufl.edu

352-273-8008


Be an Informed Participant

Before deciding to participate in a research study, take time to learn about clinical research, how it's conducted and your rights as a research participant. Following are some helpful resources from independent sources. Always remember that a clinical research study is research, not treatment.

Know Who to Contact

  • Eligibility: For questions about a specific study and who is eligible to participate, call or email the contact person listed for that study.
  • Your Rights: For questions about your rights as a research participant, contact the UF Institutional Review Boards at 352-273-9600.
  • Feedback: For general questions or feedback about study listings, email the UF Clinical and Translational Science Institute at CTSI-Studies-L@lists.ufl.edu.

Other Resources

  • HealthStreet: Health-focused services, classes and events, and opportunities to participate in research.
  • ResearchMatch.org: Join a national registry of volunteers willing to be contacted about research studies.

For Research Teams